Cingulate Therapeutics

Cingulate Therapeutics, LLC (CTx) is a privately held, clinical-stage biopharmaceutical company focused on the development of innovative new products utilizing the Company’s disruptive, proprietary Precision Timed Release™ (PTR™) drug delivery platform technology incorporating a proprietary Erosion Barrier Layer (EBL) enabling the creation of true once-daily, multi-dose tablets.

Cingulate™ is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. CTx-1301 and CTx-1302 utilize an innovative, versatile platform technology that enables the formulation and manufacturing of multi-dose tablets designed to deliver a rapid onset and last the entire active day while providing a controlled descent of drug concentration in the body to optimize treatment.